- Conditions: Diabetes; Diabetes Mellitus, Type 1
Interventions: Drug: insulin degludec; Drug: insulin glargine
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified April 2012 - Condition: Type 2 Diabetes
Interventions: Drug: "GLIPULIN:" [insulin glargine, metformin, exenatide (GLP-1-agonist)]; Drug: Insulin glargine, metformin, prandial insulin
Sponsors: University of Washington; University of Washington; Eli Lilly and Company; Sanofi-Aventis; Amylin Pharmaceuticals, Inc.; DexCom, Inc.; Bayer; Medicomp; University of Texas; Department of Veterans Affairs; Biomedical Research Institute of New Mexico
Not yet recruiting - verified February 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: HOE 901 - New formulation of insulin glargine; Drug: HOE 901 - Insulin glargine
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: HOE 901 - Insulin glargine; Drug: HOE901 - Insulin glargine-new formulation
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Intervention: Drug: PB1023 Injection
Sponsors: PhaseBio Pharmaceuticals Inc.; PhaseBio Pharmaceuticals Inc.
Recruiting - verified January 2012 - Condition: Type 2 Diabetes
Intervention: Behavioral: High Glycemic Diet
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified April 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: GK1-399 (formerly TTP399); Drug: GK1-399 (formerly TTP399); Drug: GK1-399 (formerly TTP399); Drug: Placebo
Sponsors: Forest Laboratories; Forest Laboratories
Recruiting - verified January 2012 - Conditions: Type 2 Diabetes; Metabolic Syndrome
Intervention: Other: water, glucose with or without amino acid
Sponsors: Minneapolis Veterans Affairs Medical Center; Minneapolis Veterans Affairs Medical Center
Recruiting - verified November 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: LY2605541; Drug: Insulin Glargine; Drug: Insulin Lispro
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: GSK2376497; Drug: 0.9% sodium chloride
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012 - Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Glargine; Drug: LY2605541; Drug: Insulin Lispro
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Technosphere Insulin; Drug: Technosphere Inhalation Powder
Sponsors: Mannkind Corporation; Mannkind Corporation
Recruiting - verified May 2012 - Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Technosphere Insulin with MedToneC Inhaler in combination with a basal insulin; Drug: Technosphere Insulin with Gen2C Inhaler in combination with a basal insulin; Drug: Insulin Aspart in combination with a basal insulin
Sponsors: Mannkind Corporation; Mannkind Corporation
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo matching with Saxagliptin; Drug: Metformin IR; Drug: Metformin XR; Drug: Saxagliptin; Drug: Saxagliptin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Not yet recruiting - verified February 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Single Dose PB1023; Drug: Single Dose PB1023
Sponsors: PhaseBio Pharmaceuticals Inc.; PhaseBio Pharmaceuticals Inc.
Recruiting - verified February 2012 - Conditions: Cardiovascular Disease; Diabetes Mellitus, Type 2
Interventions: Drug: Dulaglutide; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Diabetes Mellitus Type 1 and 2; Diabetes Mellitus Complications; Gastroparesis; Gastrointestinal Motility Disorder
Interventions: Drug: RM-131; Drug: Placebo
Sponsors: Rhythm Pharmaceuticals, Inc.; Rhythm Pharmaceuticals, Inc.
Recruiting - verified March 2012 - Conditions: Type I Diabetes Mellitus Without Complication; Eating Disorder
Intervention:
Sponsors: Park Nicollet Institute; Park Nicollet Institute; Park Nicollet Foundation; Melrose Institute; International Diabetes Center at Park Nicollet
Not yet recruiting - verified February 2012 - Conditions: Wounds; Diabetes Complications; Diabetic Foot; Foot Ulcer
Intervention: Other: Online Wound Electronic Medical Record
Sponsors: New York University School of Medicine; New York University School of Medicine; Agency for Healthcare Research and Quality (AHRQ)
Recruiting - verified March 2012 - Conditions: Acute Ischemic Stroke; Diabetes; Hyperglycemia
Interventions: Drug: IV insulin to maintain target glucose concentration of 80-130 mg/dL; Drug: Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL
Sponsors: University of Virginia; University of Virginia; Neurological Emergencies Treatment Trials Network (NETT); Medical University of South Carolina; Medical Automation Systems, an Alere Company; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2012 - Conditions: Overweight; Obese; Obesity; Diabetic; Type 2 Diabetes
Interventions: Other: Higher Carbohydrate, Lower Fat Diet; Other: Lower carbohydrate, Higher fat diet; Other: Individualized Counseling
Sponsors: University of California, San Diego; University of California, San Diego; HealthPartners Research Foundation; University of Minnesota - Clinical and Translational Science Institute
Recruiting - verified February 2012 - Conditions: Diabetes; Diabetic Retinopathy
Intervention: Behavioral: Diabetes Education
Sponsors: Diabetic Retinopathy Clinical Research Network; Diabetic Retinopathy Clinical Research Network; National Eye Institute (NEI); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified April 2012 - Condition: Diabetes
Interventions: Device: blood pressure with telemetry; Device: Home blood pressure monitor without telemetry
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified January 2012 - Conditions: Hypertension; Hyperlipidemia; Diabetes; Smoking
Intervention: Behavioral: Prioritized Clinical Decision Support
Sponsors: HealthPartners Research Foundation; HealthPartners Research Foundation; National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting - verified November 2011 - Conditions: Renal Insufficiency, Chronic; Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Bardoxolone Methyl: 20 mg
Sponsors: Reata Pharmaceuticals, Inc.; Reata Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: glimepride placebo; Drug: linagliptin placebo; Drug: linagliptin; Drug: glimepiride
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Type 2 Diabetes
Intervention:
Sponsors: Park Nicollet Institute; Park Nicollet Institute; International Diabetes Center at Park Nicollet; Sanofi-Aventis
Recruiting - verified February 2012 - Condition: Foot Ulcers, Diabetic
Intervention: Device: PriMatrix
Sponsors: TEI Biosciences Inc.; TEI Biosciences Inc.; Mayo Clinic; California School of Podiatric Medicine; New York College of Podiatric Medicine; Temple University
Recruiting - verified June 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Insulin lispro; Drug: Glargine
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Pancreatitis; Diabetes
Interventions: Drug: Sitagliptin; Drug: Placebo
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute
Recruiting - verified August 2011 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Exenatide Once Weekly; Drug: Placebo
Sponsors: Amylin Pharmaceuticals, Inc.; Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
Recruiting - verified December 2011 - Condition: Acute Coronary Syndrome
Interventions: Drug: lixisenatide (AVE0010); Drug: placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Dapagliflozin; Drug: Placebo matching Dapagliflozin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified November 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo BI 10773 low dose; Drug: Placebo BI 10773 low dose; Drug: Placebo BI 10773 high dose; Drug: Placebo BI 10773 high dose; Drug: BI 10773 low dose; Drug: BI 10773 high dose
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Cystic Fibrosis Related Diabetes
Intervention:
Sponsors: Johns Hopkins University; Johns Hopkins University; Cystic Fibrosis Foundation; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University of Minnesota - Clinical and Translational Science Institute; Vanderbilt University; Northwestern University; Emory University
Recruiting - verified June 2011 - Conditions: Obesity; Diabetes
Interventions: Procedure: Adjustable gastric banding; Behavioral: Dietary and lifestyle modification
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified December 2011 - Condition: Type 2 Diabetes
Interventions: Drug: Exenatide; Drug: Insulin Glargine
Sponsors: Park Nicollet Institute; Park Nicollet Institute; International Diabetes Center at Park Nicollet; Sanofi-Aventis
Recruiting - verified February 2012 - Conditions: Type 1 Diabetes; Hypoglycemia Unawareness
Interventions: Drug: Naltrexone; Drug: Naltrexone
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); American Diabetes Association
Recruiting - verified August 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Aleglitazar; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified March 2012 - Conditions: Autoantibody Positive; Non-diabetic Relatives at Risk for Type 1 Diabetes; High Risk; Impaired Glucose Tolerance
Intervention: Drug: Teplizumab
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR); Juvenile Diabetes Research Foundation; American Diabetes Association
Recruiting - verified February 2012 - Conditions: Coronary Artery Disease; Diabetes Mellitus Type 2
Intervention: Drug: Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere
Sponsors: Mayo Clinic; Mayo Clinic; University of Nebraska; Astellas Pharma US, Inc.; Lantheus Medical Imaging
Recruiting - verified January 2012 - Conditions: Chronic Periodontitis; Type 2 Diabetes
Interventions: Procedure: Non-surgical periodontal treatment; Other: Delayed non-surgical periodontal therapy
Sponsors: Stony Brook University; Stony Brook University; University of Alabama at Birmingham; University of Minnesota - Clinical and Translational Science Institute; The University of Texas Health Science Center, Houston; University of Texas; National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting - verified December 2011 - Conditions: Vitreous Hemorrhage; Proliferative Diabetic Retinopathy
Interventions: Drug: Ranibizumab; Behavioral: Saline
Sponsors: Diabetic Retinopathy Clinical Research Network; Diabetic Retinopathy Clinical Research Network; National Eye Institute (NEI)
Recruiting - verified February 2012 - Conditions: Diabetes Mellitus, Type 2; Acute Coronary Syndrome
Interventions: Drug: Alogliptin; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2012 - Conditions: Type 1 Diabetes; Eating Disorder
Intervention:
Sponsors: Park Nicollet Institute; Park Nicollet Institute; International Diabetes Center at Park Nicollet; Park Nicollet Eating Disorder Institute; Park Nicollet Foundation
Recruiting - verified February 2012 - Conditions: Malignant Neoplasm Overlapping Lip Site; Mouth Neoplasms; Malignant Neoplasm of Other and Ill-defined Sites in the Lip, Oral Cavity and Pharynx; Leukoplakia; Other Lesions of Oral Mucosa; Pigmented Oral Mucosal Lesion; Unspecified Lesions of Oral Mucosa; Oral Lichenoid Lesions; Premalignant Lesion; Other and Unspecified Lesions of Oral Mucosa; Granuloma and Granuloma-like Lesions of Oral Mucosa; Diseases of the Oral Soft Tissue, Excluding Lesions Specific for Gingiva and Tongue; Oral Premalignant Lesion; Oral Premalignant Neoplasms; Oral Leukoplakia
Interventions: Drug: Pioglitazone; Drug: Placebo
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI); University of Minnesota - Clinical and Translational Science Institute; Memorial Sloan-Kettering Cancer Center; University of Wisconsin, Madison; University of Alabama at Birmingham; University of Iowa; University of Maryland; Roswell Park Cancer Institute; Columbia University; Weill Medical College of Cornell University; European Institute of Oncology
Recruiting - verified April 2012 - Conditions: Diabetes Mellitus, Type 2; Insulin Resistance; Dyslipidemias
Intervention:
Sponsors: Mayo Clinic; Mayo Clinic; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2012 - Conditions: Type 1 Diabetes; Hypoglycemia Unawareness
Intervention:
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute
Recruiting - verified August 2011 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin phosphate; Drug: Placebo
Sponsors: Merck; Merck; Duke Clinical Research Institute, Oxford Diabetes Trials Unit
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Welchol; Drug: placebo tablets
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified January 2012 - Condition: Type 1 Diabetes
Intervention:
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute
Recruiting - verified August 2011 - Condition: Diabetes Mellitus
Intervention:
Sponsors: Mayo Clinic; Mayo Clinic
Not yet recruiting - verified July 2011 - Conditions: Kidney Disease; Nephropathy; Type 2 Diabetes
Interventions: Drug: losartan; Drug: lisinopril; Drug: losartan
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified May 2012 - Condition: Type 1 Diabetes Mellitus
Intervention: Procedure: Islet transplant
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified December 2011 - Condition: Diabetes Mellitus, Type 1
Intervention: Drug: Oral Insulin
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Allergy and Infectious Diseases (NIAID); National Center for Research Resources (NCRR); American Diabetes Association; Juvenile Diabetes Research Foundation
Recruiting - verified February 2012 - Condition: Diabetes Mellitus
Intervention:
Sponsors: University of Minnesota - Clinical and Translational Science Institute; Michael Mauer, MD; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institutes of Health (NIH)
Recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 1
Intervention:
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR); Juvenile Diabetes Research Foundation; American Diabetes Association
Recruiting - verified March 2012 - Conditions: Stroke; Myocardial Infarction; Diabetes
Interventions: Drug: pioglitazone; Drug: placebo
Sponsors: Yale University; Yale University; National Institute of Neurological Disorders and Stroke (NINDS); Takeda Pharmaceuticals North America, Inc.
Recruiting - verified August 2011
 |
Join Clinical Trials in Minnesota for Diabetes |
